Terry Ann Fortin
Associate Professor of Medicine
Current Appointments & Affiliations
- Associate Professor of Medicine, Medicine, Cardiology, Medicine 2021
Contact Information
- 126A Hanes House, Durham, NC 27710
- Duke Box 102351, Durham, NC 27710
-
forti003@mc.duke.edu
(919) 684-6237
- Background
-
Education, Training, & Certifications
- Fellow in Cardiology, Medicine, Duke University 2002 - 2006
- Medical Resident, Medicine, Duke University 1999 - 2002
- M.D., University of Massachusetts, Amherst 1999
-
Previous Appointments & Affiliations
- Associate Professor of Medicine, Medicine, Cardiology, Medicine 2018 - 2020
- Assistant Professor of Medicine, Medicine, Cardiology, Medicine 2011 - 2018
- Assistant Professor of Medicine, Medicine, Cardiology, Medicine 2009 - 2011
- Medical Instructor in the Department of Medicine, Medicine, Cardiology, Medicine 2006 - 2008
- Instructor, Temporary in the Department of Medicine, Medicine, Cardiology, Medicine 2006
- Research
-
Selected Grants
- A011-12 SOTERIA (An Open-Label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH) 2022 - 2027
- ZENITH A011-14 (A Phase 3, Randomized, Double-Blind, Placebo- Controlled Study to Evaluate Sotatercept When Added to Maximum Tolerated Background Therapy in Participants With Pulmonary Arterial Hypertension (PAH) WorldHealth Organization (WHO) 2022 - 2026
- Acceleron A011-11 Stellar 2021 - 2025
- AC-065B302 Select: Radomized double blind placebo controlled parallel group group sequential adaptive Phase 3 study with open label extention period to assess efficacy and safety of Selexipag 2019 - 2024
- 14th Annual Pulmonary Hypertension Symposium 2022 - 2024
- APD-811-303 2019 - 2024
- US - Base, observational, drug registry of Opsumit (macitentan) new users in clinical practice (OPUS Registry) 2015 - 2023
- Phase III of Treprostinil in patients with PH-COPD 2018 - 2023
- APD 811-301 - Phase III 2019 - 2023
- 13th Annual Pulmonary Hypertension Symposium 2021 - 2022
- Uptravi® (SelexiPag): tHe usErs dRug rEgistry 2017 - 2022
- 13th Annual Pulmonary Hypertension Symposium 2021
- 12th Annual Pulmonary Hypertension Symposium 2020 - 2021
- United States Pulmonary Hypertension Scientific Registry 2016 - 2021
- BEAT- An Open label extension of BPS-314d-MR-PAH-303 2018 - 2020
- 11th Annual Pulmonary Hypertension Symposium 2019
- BPS-314d-MR-PAH-302. BEAT: A Multicenter, Doubled-Blind, Randomized, Placebo-Controlled, Phase 3 Study To Assess The Efficacy And Safety of Oral B. 2014 - 2019
- CardioMEMS 2016 - 2018
- Multicenter, open-label, single-group study to assess the tolerability and the safety of the TRANSITion from inhaled treprostinil to oral selexipag in adult patients with pulmonary arterial hypertension. 2016 - 2018
- National Biological Sample and Data Repository for PAH 2016 - 2018
-
External Relationships
- Acceleron Pharma
- Actelion Pharmaceuticals Ltd. bought by Janssen (Johnson & Johnson)
- Enzyvant Therapeutics
- Janssen Research & Development
- Liquidia
- Lung LLC/Lung Biotechnology
- Merck Sharp & Dohme Inc., One Merck Drive, Whitehouse Station, NJ 08889-0100.
- Pulmonary Hypertension Association/US PH registry
- United Therapeutics Corp.
- Publications & Artistic Works
-
Selected Publications
-
Academic Articles
-
Rao, Vishal N., Michelle D. Kelsey, Michael A. Blazing, Neha J. Pagidipati, Terry A. Fortin, and Marat Fudim. “Unexplained Dyspnea on Exertion: The Difference the Right Test Can Make.” Circ Heart Fail 15, no. 2 (February 2022): e008982. https://doi.org/10.1161/CIRCHEARTFAILURE.121.008982.Full Text Link to Item
-
Zhu, Na, Emilia M. Swietlik, Carrie L. Welch, Michael W. Pauciulo, Jacob J. Hagen, Xueya Zhou, Yicheng Guo, et al. “Rare variant analysis of 4241 pulmonary arterial hypertension cases from an international consortium implicates FBLN2, PDGFD, and rare de novo variants in PAH.” Genome Med 13, no. 1 (May 10, 2021): 80. https://doi.org/10.1186/s13073-021-00891-1.Full Text Link to Item
-
Barbas, Andrew S., Jacob N. Schroder, Deeplaxmi P. Borle, Arturo Suarez, Nader Abraham, Michael W. Manning, Timothy E. Miller, et al. “Planned Initiation of Venoarterial Extracorporeal Membrane Oxygenation Prior to Liver Transplantation in a Patient With Severe Portopulmonary Hypertension.” Liver Transpl 27, no. 5 (May 2021): 760–62. https://doi.org/10.1002/lt.25871.Full Text Link to Item
-
Badlam, Jessica B., David B. Badesch, Eric D. Austin, Raymond L. Benza, Wendy K. Chung, Harrison W. Farber, Kathy Feldkircher, et al. “United States Pulmonary Hypertension Scientific Registry: Baseline Characteristics.” Chest 159, no. 1 (January 2021): 311–27. https://doi.org/10.1016/j.chest.2020.07.088.Full Text Link to Item
-
Swaminathan, Aparna C., Hongmei Zhu, Victor Tapson, Yuliya Lokhnygina, Abby Poms, Zach Kelleher, Elijah Gaspard, et al. “Treatment-related biomarkers in pulmonary hypertension patients on oral therapies.” Respir Res 21, no. 1 (November 19, 2020): 304. https://doi.org/10.1186/s12931-020-01566-y.Full Text Open Access Copy Link to Item
-
Parikh, Kishan S., Sean Doerfler, Nicholas Shelburne, Karla Kennedy, Jordan Whitson, Talal Dahhan, Terry Fortin, and Sudarshan Rajagopal. “Experience in Transitioning From Parenteral Prostacyclins to Selexipag in Pulmonary Arterial Hypertension.” J Cardiovasc Pharmacol 75, no. 4 (April 2020): 299–304. https://doi.org/10.1097/FJC.0000000000000800.Full Text Open Access Copy Link to Item
-
Parikh, Kishan S., Talal Dahhan, Leigh Nicholl, Nicole Ruopp, Gina-Maria Pomann, Terry Fortin, Victor F. Tapson, and Sudarshan Rajagopal. “Clinical Features and Outcomes of Patients with Sarcoidosis-associated Pulmonary Hypertension.” Sci Rep 9, no. 1 (March 11, 2019): 4061. https://doi.org/10.1038/s41598-019-40030-w.Full Text Open Access Copy Link to Item
-
Rhodes, Christopher J., Ken Batai, Marta Bleda, Matthias Haimel, Laura Southgate, Marine Germain, Michael W. Pauciulo, et al. “Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis.” Lancet Respir Med 7, no. 3 (March 2019): 227–38. https://doi.org/10.1016/S2213-2600(18)30409-0.Full Text Link to Item
-
Frost, Adaani, Munir Janmohamed, Jason S. Fritz, John W. McConnell, David Poch, Terry Ann Fortin, Chad E. Miller, et al. “Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study.” J Heart Lung Transplant 38, no. 1 (January 2019): 43–50. https://doi.org/10.1016/j.healun.2018.09.003.Full Text Link to Item
-
Parikh, Kishan S., Sudarshan Rajagopal, Terry Fortin, Victor F. Tapson, and Abby D. Poms. “Safety and Tolerability of High-dose Inhaled Treprostinil in Pulmonary Hypertension.” J Cardiovasc Pharmacol 67, no. 4 (April 2016): 322–25. https://doi.org/10.1097/FJC.0000000000000357.Full Text Link to Item
-
Rajagopal, Sudarshan, Daniel E. Forsha, Niels Risum, Christoph P. Hornik, Abby D. Poms, Terry A. Fortin, Victor F. Tapson, Eric J. Velazquez, Joseph Kisslo, and Zainab Samad. “Comprehensive assessment of right ventricular function in patients with pulmonary hypertension with global longitudinal peak systolic strain derived from multiple right ventricular views.” J Am Soc Echocardiogr 27, no. 6 (June 2014): 657-665.e3. https://doi.org/10.1016/j.echo.2014.02.001.Full Text Link to Item
-
Meine, Trip J., Manesh R. Patel, John Heitner, Terry A. Fortin, Robert A. Pagnanelli, Thomas R. Gehrig, Raymond Kim, and Salvador Borges-Neto. “Cardiac imaging impaired by a silicone breast implant.” Clin Nucl Med 30, no. 4 (April 2005): 262–64. https://doi.org/10.1097/01.rlu.0000156378.61359.bd.Full Text Link to Item
-
McGoon, Michael, David Gutterman, Virginia Steen, Robin Barst, Douglas C. McCrory, Terry A. Fortin, James E. Loyd, and James E. American College of Chest Physicians. “Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines.” Chest 126, no. 1 Suppl (July 2004): 14S-34S. https://doi.org/10.1378/chest.126.1_suppl.14S.Full Text Link to Item
-
McLaughlin, Vallerie V., Kenneth W. Presberg, Ramona L. Doyle, Steven H. Abman, Douglas C. McCrory, Terry Fortin, Gregory Ahearn, and Gregory American College of Chest Physicians. “Prognosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines.” Chest 126, no. 1 Suppl (July 2004): 78S-92S. https://doi.org/10.1378/chest.126.1_suppl.78S.Full Text Link to Item
-
Ramanathan, K. B., E. D. Folland, T. Fortin, P. Hartigan, C. A. Boucher, and A. F. Parisi. “Accuracy and limitations of planar thallium scintigraphy for identifying the involved coronary artery in patients with single-vessel disease: Findings in the ACME trial.” Cardiovascular Reviews and Reports 22, no. 2 (January 1, 2001): 115–20.
-
Gibson, C. M., C. P. Cannon, W. L. Daley, J. T. Dodge, B. Alexander, S. J. Marble, C. H. McCabe, et al. “TIMI frame count: a quantitative method of assessing coronary artery flow.” Circulation 93, no. 5 (March 1, 1996): 879–88. https://doi.org/10.1161/01.cir.93.5.879.Full Text Link to Item
-
Strauss, W. E., T. Fortin, P. Hartigan, E. D. Folland, and A. F. Parisi. “A comparison of quality of life scores in patients with angina pectoris after angioplasty compared with after medical therapy. Outcomes of a randomized clinical trial. Veterans Affairs Study of Angioplasty Compared to Medical Therapy Investigators.” Circulation 92, no. 7 (October 1, 1995): 1710–19. https://doi.org/10.1161/01.cir.92.7.1710.Full Text Link to Item
-
Folland, E. D., R. A. Vogel, P. Hartigan, E. R. Bates, G. J. Beauman, T. Fortin, C. Boucher, and A. F. Parisi. “Relation between coronary artery stenosis assessed by visual, caliper, and computer methods and exercise capacity in patients with single-vessel coronary artery disease. The Veterans Affairs ACME Investigators.” Circulation 89, no. 5 (May 1994): 2005–14. https://doi.org/10.1161/01.cir.89.5.2005.Full Text Link to Item
-
-
Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.